Literature DB >> 8579218

Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children.

H Yamamoto1, H Murakami, K Horiguchi, B Egawa.   

Abstract

Kynurenic acid (KYA), the only known endogenous antagonist of the excitatory amino acids, is a metabolite of kynurenine. In the present study the levels of KYA were measured in the cerebrospinal fluid (CSF) of epileptic children and age-matched controls to investigate the relationship between various forms of epilepsy and KYA levels. CSF samples from four patients with West syndrome (WS), four patients with epilepsy with grand mal seizures on awakening (EGSA), and four patients with childhood epilepsy with occipital paroxysms (CEOP) were collected by lumbar puncture before treatment. The concentration of CSF KYA was analyzed by HPLC with electrochemical detection and compared with those of age-matched controls. The levels of CSF KYA were significantly lower (P < 0.05) in patients with WS compared with controls. The levels of CSF KYA in patients with EGSA and with CEOP did not differ significantly from control levels. These results suggest that the presence of seizures in WS is associated with altered kynurenine metabolism. The possibility that seizures in WS may be related to decreased production of KYA is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8579218     DOI: 10.1016/0387-7604(95)00065-j

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  9 in total

1.  Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93).

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Etsuo Okuno; Martyna Kandefer-Szerszen; Jan Albrecht; Waldemar A Turski
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

3.  A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study : special issue related to kynurenine.

Authors:  Ildikó Demeter; Károly Nagy; Levente Gellért; László Vécsei; Ferenc Fülöp; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

Review 4.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  The Janus-face kynurenic acid.

Authors:  Eva Rózsa; Hermina Robotka; László Vécsei; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2008-04-30       Impact factor: 3.575

6.  Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor.

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Jolanta Parada-Turska; Barbara Zdzisinska; Robert Rejdak; Tomasz Kocki; Etsuo Okuno; Martyna Kandefer-Szerszen; Eberhart Zrenner; Waldemar A Turski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-10       Impact factor: 3.000

7.  The Kynurenine Pathway is Differentially Activated in Children with Lyme Disease and Tick-Borne Encephalitis.

Authors:  Ronny Wickström; Åsa Fowler; Michel Goiny; Vincent Millischer; Sofia Ygberg; Lilly Schwieler
Journal:  Microorganisms       Date:  2021-02-04

Review 8.  A Review of the Health Benefits of Food Enriched with Kynurenic Acid.

Authors:  Monika Turska; Piotr Paluszkiewicz; Waldemar A Turski; Jolanta Parada-Turska
Journal:  Nutrients       Date:  2022-10-08       Impact factor: 6.706

Review 9.  Kynurenic Acid in the digestive system-new facts, new challenges.

Authors:  Michal P Turski; Monika Turska; Piotr Paluszkiewicz; Jolanta Parada-Turska; Gregory F Oxenkrug
Journal:  Int J Tryptophan Res       Date:  2013-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.